2013/08/29 by Kelly E. Caudle, Caroline F. Thorn, Teri E. Klein +4 · 323 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Biochemical and Molecular Research #Biology #Cancer #Capecitabine #Chemotherapy #Colorectal Cancer Treatments and Studies #Colorectal cancer #DPYD #Dihydropyrimidine dehydrogenase #Dosing #Fluorouracil #Gene #Genetics #Genotype #Internal medicine #Medicine #Oncology #Pancreatic and Hepatic Oncology Research #Pharmacogenetics #Pharmacology #Thymidylate synthase
paper · pdf · doi:10.1038/clpt.2013.172
published in Clinical Pharmacology & Therapeutics 94(6), 640-645 (Wiley)
openalex publication_date 2013/08/29 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org).